Clinical, biochemical, and molecular analysis of combined methylmalonic acidemia and hyperhomocysteinemia (cblC type) in China
- 6 October 2010
- journal article
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 33 (S3), 435-442
- https://doi.org/10.1007/s10545-010-9217-0
Abstract
The most common inborn error of cobalamin (cbl) metabolism in China is the cblC type characterized by combined methylmalonic acidemia and hyperhomocysteinemia. The clinical presentation is relatively nonspecific, such as feeding difficulty, recurrent vomiting, hypotonia, lethargy, seizures, progressive developmental delay, and mental retardation, together with anemia and metabolic acidosis. More specific biochemical findings include high levels of propionylcarnitine (C3), free carnitine (C3/C0), and acetylcarnitine (C3/C2) measured by tandem mass spectrometry (MS/MS), elevation of methylmalonic acid (MMA) measured by gas chromatography–mass spectrometry (GC-MS), and increased total homocysteine with normal or decreased methionine. We report on 50 Chinese patients with combined methylmalonic acidemia and hyperhomocysteinemia. Forty-six belonged to the cblC complementation group. Mutation analysis of the MMACHC gene was performed to characterize the mutational spectrum of cblC deficiency, and 17 different mutations were found. Most were clustered in exons 3 and 4, accounting for 91.3% of all mutant alleles. Two mutations were novel, namely, c.315 C>G (p.Y105X) and c.470 G>C(p.W157S). In terms of genotype–phenotype correlation, the c.609 G>A mutation was associated with early-onset disease when homozygous. Unlike previous reports from other populations, c.609 G>A (p.W203X) was the most frequent cblC mutation detected in our study of Chinese patients, affecting 51 of 92 MMACHC alleles (55.4%). The high prevalence of this nonsense mutation could have potential therapeutic significance for Chinese cblC patients. Besides traditional approaches consisting of hydroxocobalamin injections, carnitine, betaine, and protein restriction, novel drugs that target premature termination codons may have a role in the future.Keywords
This publication has 28 references indexed in Scilit:
- Hydroxocobalamin dose escalation improves metabolic control in cblCJournal of Inherited Metabolic Disease, 2009
- Processing of alkylcobalamins in mammalian cells: A role for the MMACHC (cblC) gene productMolecular Genetics and Metabolism, 2009
- Identification of a putative lysosomal cobalamin exporter altered in the cblF defect of vitamin B12 metabolismNature Genetics, 2009
- Decyanation of vitamin B 12 by a trafficking chaperoneProceedings of the National Academy of Sciences of the United States of America, 2008
- PTC124 targets genetic disorders caused by nonsense mutationsNature, 2007
- Selective screening for inborn errors of metabolism on clinical patients using tandem mass spectrometry in China: A four‐year reportJournal of Inherited Metabolic Disease, 2007
- Combined methylmalonic aciduria and homocystinuria (cblC): Phenotype–genotype correlations and ethnic-specific observationsMolecular Genetics and Metabolism, 2006
- Subacute combined degeneration of the spinal cord in cblC disorder despite treatment with B12Molecular Genetics and Metabolism, 2006
- Gene discovery in methylmalonic aciduria and homocystinuriaClinical Genetics, 2006
- Identification of the gene responsible for methylmalonic aciduria and homocystinuria, cblC typeNature Genetics, 2005